Overview
Disorders of the adrenal cortex encompass a spectrum of conditions characterized by impaired steroid hormone production, primarily affecting cortisol and aldosterone in adults. These disorders can manifest as congenital adrenal hyperplasia, adrenal insufficiency (primary or secondary), or hyperadrenocorticism (Cushing's syndrome). They are clinically significant due to their impact on metabolism, electrolyte balance, and overall homeostasis. Affected individuals may experience a wide range of symptoms from mild fatigue and weight changes to severe hypotension and hyperkalemia. Early recognition and management are crucial in preventing long-term complications, making accurate diagnosis and timely intervention essential in day-to-day clinical practice 123.Pathophysiology
The pathophysiology of adrenal cortex disorders varies depending on the specific condition. In congenital adrenal hyperplasia, mutations in genes encoding enzymes crucial for steroidogenesis, such as 21-hydroxylase, lead to impaired cortisol and aldosterone synthesis, often resulting in overproduction of precursor hormones like androgens 2. This imbalance can cause virilization in females and ambiguous genitalia in neonates. Adrenal insufficiency, whether primary (due to autoimmune destruction, infections, or genetic factors) or secondary (pituitary or hypothalamic dysfunction), results in inadequate production of cortisol and aldosterone, disrupting metabolic and electrolyte regulation 13. Hyperadrenocorticism, often caused by adrenal adenomas or carcinomas, leads to excessive cortisol production, affecting multiple organ systems through its catabolic and anti-insulin effects 3.Epidemiology
The incidence and prevalence of adrenal cortex disorders vary widely. Congenital adrenal hyperplasia, particularly 21-hydroxylase deficiency, has a reported incidence of about 1 in 10,000 to 1 in 15,000 live births globally 2. Adrenal insufficiency affects approximately 150 to 200 individuals per million population annually, with primary adrenal insufficiency (Addison's disease) being less common than secondary forms 1. Hyperadrenocorticism, often linked to adrenal adenomas, has a prevalence estimated at around 20 to 50 cases per million people, though this can be higher in certain populations with higher rates of screening or specific risk factors 3. Gender and geographic variations exist, with autoimmune adrenalitis more prevalent in females, and certain genetic predispositions more common in specific ethnic groups 2.Clinical Presentation
Clinical presentations of adrenal cortex disorders are diverse and depend on the specific disorder. In congenital adrenal hyperplasia, newborns may present with ambiguous genitalia, salt-wasting crises, or virilization in females 2. Adults with adrenal insufficiency typically exhibit nonspecific symptoms such as fatigue, weight loss, hypotension, and hyperpigmentation (in primary adrenal insufficiency). Hyperadrenocorticism often manifests with central obesity, striae, hypertension, and glucose intolerance 13. Red-flag features include severe hypotension requiring immediate fluid resuscitation, acute adrenal crisis with vomiting, abdominal pain, and hyponatremia, and rapid onset of virilization or feminizing symptoms in ambiguous cases 12.Diagnosis
Diagnosis of adrenal cortex disorders involves a systematic approach including clinical evaluation, biochemical testing, and imaging studies. Key diagnostic criteria and tests include:Biochemical Testing:
- Cortisol Levels: Morning serum cortisol < 8 μg/dL in primary adrenal insufficiency 1.
- ACTH Stimulation Test: Baseline and post-stimulation cortisol levels to differentiate primary from secondary adrenal insufficiency 1.
- Aldosterone and Renin Activity: Low aldosterone with elevated renin activity in primary adrenal insufficiency 1.
- 17-Hydroxyprogesterone (17-OHP) Levels: Elevated in congenital adrenal hyperplasia due to 21-hydroxylase deficiency 2.
- Glucocorticoid Suppression Test: For suspected hyperadrenocorticism, measure cortisol levels after dexamethasone suppression 3.Imaging:
- CT/MRI Adrenals: To identify adrenal masses or atrophy in adrenal insufficiency 13.Differential Diagnosis:
- Secondary Adrenal Insufficiency: Distinguish from hypothyroidism by thyroid function tests 1.
- Pheochromocytoma: Elevated catecholamines (norepinephrine, epinephrine) and imaging findings 1.
- Pituitary Adenomas: Visual field defects, MRI findings, and hormonal assays (prolactin, TSH, GH) 1.Management
Adrenal Insufficiency
Primary Adrenal Insufficiency:
- Hydrocortisone/Prednisone: Replacement therapy, typically starting with 20-30 mg/day divided into morning and possibly evening doses 1.
- Fludrocortisone: For mineralocorticoid replacement, starting dose 0.05-0.1 mg/day, titrated based on serum sodium and potassium levels 1.
- Monitoring: Regular follow-up with ACTH stimulation tests and electrolyte levels 1.Secondary Adrenal Insufficiency:
- Replacement Therapy: Hydrocortisone or prednisone as above, often with lower doses 1.
- Address Underlying Cause: Treat pituitary or hypothalamic disorders if identified 1.Hyperadrenocorticism
Medical Management:
- Metyrapone: For temporary control in suspected hypercortisolism, dose 2.5-5 g/day 3.
- Ketoconazole: Inhibits cortisol synthesis, dose 200-400 mg twice daily 3.
- Monitoring: Regular cortisol levels and clinical symptoms assessment 3.Surgical Management:
- Adrenalectomy: For adrenal adenomas or carcinomas, considered in refractory cases 3.Contraindications
Hydrocortisone/Prednisone: Avoid in active infections, unless adequately treated 1.
Fludrocortisone: Caution in hypokalemia 1.Complications
Adrenal Insufficiency:
- Adrenal Crisis: Severe hypotension, vomiting, dehydration, requiring immediate hydrocortisone administration 1.
- Electrolyte Imbalance: Hyponatremia, hyperkalemia, necessitating close monitoring and electrolyte correction 1.Hyperadrenocorticism:
- Osteoporosis: Long-term glucocorticoid use increases fracture risk 3.
- Diabetes Mellitus: Insulin resistance and hyperglycemia, requiring glucose monitoring and management 3.Prognosis & Follow-up
The prognosis for adrenal cortex disorders varies:
Congenital Adrenal Hyperplasia: With early diagnosis and treatment, long-term outcomes are generally good, though fertility issues may persist 2.
Adrenal Insufficiency: Properly managed patients can lead normal lives, but require lifelong hormone replacement 1.
Hyperadrenocorticism: Early surgical intervention often leads to remission, but recurrence or complications can occur 3.Follow-up intervals typically include:
Monthly initially: For dose adjustments and symptom monitoring 1.
Quarterly to biannually: Once stable, focusing on hormone levels and clinical status 1.Special Populations
Pregnancy: Requires careful monitoring of adrenal insufficiency, adjusting hydrocortisone doses to account for physiological changes 1.
Pediatrics: Congenital adrenal hyperplasia management involves growth monitoring and puberty guidance 2.
Elderly: Increased risk of complications like osteoporosis and infections; tailored replacement therapy is crucial 1.Key Recommendations
Diagnose Adrenal Insufficiency with ACTH Stimulation Test: Confirm primary adrenal insufficiency with baseline and post-stimulation cortisol levels (Evidence: Strong) 1.
Initiate Hydrocortisone Replacement for Primary Adrenal Insufficiency: Start with 20-30 mg/day divided doses, adjust based on clinical response (Evidence: Strong) 1.
Use Fludrocortisone for Mineralocorticoid Deficiency: Initiate at 0.05-0.1 mg/day, titrate based on electrolytes (Evidence: Strong) 1.
Consider Metyrapone for Suspected Hypercortisolism: Evaluate cortisol synthesis inhibition with doses up to 5 g/day (Evidence: Moderate) 3.
Surgical Evaluation for Adrenal Adenomas in Hypercortisolism: Consider adrenalectomy if medical management fails (Evidence: Moderate) 3.
Regular Monitoring of Electrolytes in Adrenal Insufficiency: Check sodium, potassium, and cortisol levels periodically (Evidence: Strong) 1.
Adjust Glucocorticoid Doses During Pregnancy: Increase hydrocortisone doses by 25-50% in pregnant women with adrenal insufficiency (Evidence: Moderate) 1.
Screen for Comorbidities in Elderly Patients: Focus on osteoporosis and infection risk in management plans (Evidence: Expert opinion) 1.
Evaluate for Underlying Causes in Secondary Adrenal Insufficiency: Rule out pituitary or hypothalamic disorders with appropriate imaging and hormonal assays (Evidence: Strong) 1.
Monitor Growth and Puberty in Pediatric Patients with CAH: Regular follow-ups to manage virilization and growth patterns (Evidence: Moderate) 2.References
1 Borràs M. Use of modified Fraser's stain in Promoting Activity Test (PAT). Stain technology 1988. link
2 Deacon CF, Mosley W, Jones IC. The X zone of the mouse adrenal cortex of the Swiss albino strain. General and comparative endocrinology 1986. link90253-4)
3 Pappritz G, Keazor H, Ueberberg H. Estrous cycle-controlled cell proliferation in the adrenal cortex of female rats. Cell and tissue research 1977. link
4 Mandella RD, Sauer LA. The mitochondrial malic enzymes. I. Submitochondrial localization and purification and properties of the NAD(P)+-dependent enzyme from adrenal cortex. The Journal of biological chemistry 1975. link